16 research outputs found
multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
Funding Information: This project received funding from the European Centre for Disease Prevention and Control (ECDC) under the contract ECD.11486. Funding Information: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. Publisher Copyright: © 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.Introduction: In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim: Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods: Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results: Overall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions: VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.publishersversionpublishe
Identification of SARS-CoV-2 and Enteroviruses in Sewage Water—A Pilot Study
Due to the outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), combined with the risk of polio importation from Ukraine, we evaluated the presence of SARS-CoV-2 and enteroviruses in 25 sewage water samples from Romania, concentrated using the WHO method between January 2020 and January 2021. Surveillance for enteroviruses and SARS-CoV-2 are relevant in the calculation of prevalence estimates as well as early detection of the introduction or disappearance of these viruses. For SARS-CoV-2 detection, we used two immunochromatographic nucleocapsid antigenic tests as well as real-time PCR assays, produced for respiratory samples. The isolation of cell culture lines, in accordance with the WHO recommendations, was carried out for enterovirus detection. Twenty-three of the samples investigated were positive in rapid tests for SARS-CoV-2, while the RNA of SARS-CoV-2, detected with Respiratory 2.1 plus a panel Biofire Film array, was present in eight samples. The Allplex 2019-nCoV assay was used for the validation of the tests. There were three genes detected in one sample, E, RdPR, and N, two genes, E and RdPR, in one sample, two genes, RdPR and N, in four samples, one gene, RdPR, in five samples and one gene, N, in one sample. Eight samples were positive for non-polio enteroviruses, and no poliovirus strains were isolated. This study suggests the presence of SARS-CoV-2 and enteroviruses in Romanian sewage water in 2020. As such, our results indicate that a rapid, more specific test should be developed especially for the detection of SARS-CoV-2 in sewage water
Implementation of a Customized Safety Checklist in Gastrointestinal Endoscopy and the Importance of Team Time Out—A Dual-Center Pilot Study
Background and Objectives: Checking and correctly preparing the patient for endoscopic procedures is a mandatory step for the safety and quality of the interventions. The aim of this paper is to emphasize the importance and necessity of a “team time out” as well as the implementation of a customized “checklist” before the actual procedure. Material and Methods: We developed and implemented a checklist for the safe conduct of endoscopies and for the entire team to thoroughly know about the patient’s medical history. The subjects of this study were 15 physicians and 8 endoscopy nurses who performed overall 572 consecutive GI endoscopic procedures during the study period. Results: This is a prospective pilot study performed in the endoscopy unit of two tertiary referral medical centers. We customized a safety checklist that includes the steps to be followed before, during and after the examination. It brings together the whole team participating in the procedure in order to check the key points during the following three vital phases: before the patient falls asleep, before the endoscope is inserted and before the team leaves the examination room. The perception of team communication and teamwork was improved after the introduction of the checklist. The checklist completion rates, identity verification rates of patients by the endoscopist, adequate histological labeling management and explicit recording of follow-up recommendations are some of the parameters that improved post-intervention. Conclusions: Using a checklist and adapting it to local conditions is a high-level recommendation of the Romanian Ministry of Health. In a medical world where safety and quality are essential, a checklist could prevent medical errors, and team time out can ensure high-quality endoscopy, enhance teamwork and offer patients confidence in the medical team
Influenza viruses circulation and the effectiveness of seasonal influenza vaccine in Romania during the season 2013-2014
Circulating influenza viruses and the effectiveness of seasonal influenza vaccine in Romania, season 2012-2013 / Virusurile gripale circulante și eficacitatea vaccinului gripal sezonier în România, în sezonul 2012-2013
Scopul studiului a fost de a investiga profilul virusurilor gripale care au circulat în România în sezonul 2012- 2013 și de a estima eficacitatea vaccinului gripal sezonier, pe baza datelor de supraveghere epidemiologică si virologică. Metodă. Am testat toate probele colectate din săptămâna 40/2012 până în săptămâna 20/2013, în cadrul sistemului national de supraveghere, de la pacientii cu simptomatologie compatibilă cu gripa. Probele pozitive de gripă A/B identificate prin detecție moleculară (RT-PCR) au fost apoi caracterizate. Am utilizat hemaglutino-inhibarea pentru caracterizare antigenică si chemiluminiscenta pentru testarea sensibilitătii la antivirale. Secventierea genelor codante pentru hemaglutinină si neuraminidază si analiza lor filogenetică a fost de asemenea efectuată. Am estimat eficacitatea vaccinului gripal ca 1-odds ratio folosind un studiu caz-martor cu design negativ. Rezultate și discuții. Am testat 1087 de probe din care 537 au fost pozitive (56.2% gripă B, 40.6% A(H1N1)pdm09, 3.2% A(H3N2). Saizeci si patru dintre acestea au fost caracterizate antigenic si / sau genetic. Virusurile A(H1N1)pdm09 au fost înrudite antigenic cu tulpina vaccinală A/California/07/2009 si au apartinut grupului genetic 6 similar cu A/St. Petersburg/27/2011. Virusurile gripale tip B au apartinut cladei 2 a liniei genetice B/Yamagata, asemănătoare cu B/Estonia/55669/2011, cu excepția unei tulpini care a apartinut liniei B/ Victoria, reprezentată de tulpina B/Brisbane/60/2008. Virusurile A(H3) au apartinut grupului genetic 3C al cladei tulpinii A/Victoria/208/2009, asemănătoare cu tulpina vaccinală A/Victoria/361/2011. Toate tulpinile testate (57) au fost sensibile la oseltamivir si zanamivir. Eficacitatea vaccinală ajustată pentru gripa A(H1N1)pdm09 (N=119) a fost de 76.9% (95% CI: -113.4, 98.5), sugerând o protectie bună, în concordantă cu suprapunerea antigenică dintre tulpinile sălbatice circulante si tulpinile incluse în vaccinul recomandat pentru sezonul 2012-2013
Technical Performance, Overall Accuracy and Complications of EUS-Guided Interventional Procedures: A Dynamic Landscape
Endoscopic ultrasound (EUS) gained wide acceptance as the diagnostic and minimally invasive therapeutic approach for intra-luminal and extraluminal gastrointestinal, as well as various non-gastrointestinal lesions. Since its introduction, EUS has undergone substantial technological advances. This multi-centric study is a retrospective analysis of a prospectively maintained database of patients who underwent EUS for the evaluation of lesions located within the gastrointestinal tract and the proximal organs. It aimed to extensively assess in dynamic the dual-center EUS experience over the course of the past 20 years. Hence, we performed a population study and an overall assessment of the EUS procedures. The performance of EUS-FNA/FNB in diagnosing pancreatic neoplasms was evaluated. We also investigated the contribution of associating contrast-enhanced ultrasound imaging (CE-EUS) with EUS-FNA/FNB for differentiating solid pancreatic lesions or cystic pancreatic lesions. A total of 2935 patients undergoing EUS between 2002–2021 were included, out of which 1880 were diagnostic EUS and 1052 EUS-FNA/FNB (80% FNA and 20% FNB). Therapeutic procedures performed included endoscopic transmural drainage of pancreatic fluid collections, celiac plexus block and neurolysis, while diagnostic EUS-like CE-EUS (20%) and real-time elastography (12%) were also conducted. Most complications occurred during the first 7 days after EUS-FNA/FNB or pseudocyst drainage. EUS and the additional tools have high technical success rates and low rates of complications. The EUS methods are safe, cost effective and indispensable for the diagnostic or therapeutic management in gastroenterological everyday practice
Surveillance of medically‐attended influenza in elderly patients from Romania—data from three consecutive influenza seasons (2015/16, 2016/17, and 2017/18)
Enhanced surveillance of COVID-19 in secondary care in Europe: a tale of two waves
Background:
The I-MOVE-COVID-19 Consortium was established to conduct
surveillance of hospitalised COVID-19 cases in nine European countries,
aiming to describe the clinical and epidemiological characteristics of
severe COVID-19 in order to inform public health response.
Methods:
Data are pooled from 11 participating sites; two (England and Scotland)
submitting national data, with the remainder being from a selection
of hospitals. Descriptive analysis is performed on the pooled dataset
overall and comparing data on patients admitted from week 5 to 28 of
2020 (“first wave”) vs those admitted later (“second wave”).
Results:
Data on 84,297 hospitalised patients were submitted for 01 February 2020
- 31 January 2021. Fifty-six percent of cases (46,907/84,193) were male
and median age was 69 years. Where information was available, 44%
(25,344 /57,769) patients were recorded as having at least one chronic
condition. Ninety-five percent (7,868/8,270 and 90% (5,606/6,231)
were reported with respiratory and febrile presentations respectively.
Twenty-four percent (18,795/78,955) were admitted to intensive care
units (ICU) and 26% (19,805/76,764) died in hospital (all sites); 12%
(3,305/28,262) and 20% (5,454/27,066) respectively for all sites except
England (where ICU reporting is mandated, biasing the dataset towards
more severe outcomes as this site represents >50% of all cases). As a
percentage of all hospital admissions, both ICU admissions and deaths
decreased significantly between the first and second waves in both sexes
and across all age- groups, apart from the over 75s.
Conclusions:
Results from this multicentre European surveillance system suggest that
about one in 10 hospitalised COVID-19 patients are admitted to ICU and
one in five have fatal outcomes. Fatality and ICU admission were lower in
the second wave compared with the first.The I-MOVE-COVID-19 network has received funding from the European Commission (from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 101003673).N/
Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre study analysis by age-group, vaccine brand and time since vaccination, I-MOVE-COVID-19 and ECDC networks, July–August 2021
Introduction
In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. We measured COVID-19 vaccine effectiveness (VE) against symptomatic infection, using a multicentre test-negative study at primary care/community level in Europe.
Methods
Patients presenting with COVID-19/ARI symptoms at primary care/community level in 10 countries were tested for SARS-CoV-2. We measured complete primary course overall VE among those aged 30–44, 45–59, 60–74 and ≥75 years, and among those 30–59 and ≥60 years by vaccine brand and by time since vaccination.
Results
Overall VE was 74% (95%CI: 69–79), 76% (95%CI: 71–80), 63% (95%CI: 48–75), 63% (95%CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥75 years, respectively. VE among those aged 30–59 years was 78% (95%CI: 75–81), 66% (95%CI: 58–73), 91% (95%CI: 87–94) and 52% (95%CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among those aged ≥60 years was 67% (95%CI: 52–77), 65% (95%CI: 48–76), 83% (95%CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively.
Comirnaty VE among those aged 30–59 years was 87% (95%CI: 83–89) and 65% (95%CI: 56–71%) at 14–29 days and ≥90 days between vaccination and onset of symptoms, respectively.
Conclusions
VE against the symptomatic SARS-CoV-2 Delta variant infection varied among brands, ranging from 52–91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% ≥90 days between vaccination and onset
Acute flaccid myelitis and Guillain-Barré syndrome in children: A comparative study with evaluation of diagnostic criteria.
Background and purpose
Differentiation between acute flaccid myelitis (AFM) and Guillain–Barré syndrome (GBS) can be difficult, particularly in children. Our objective was to improve the diagnostic accuracy by giving recommendations based on a comparison of clinical features and diagnostic criteria in children with AFM or GBS.
Methods
A cohort of 26 children with AFM associated with enterovirus D68 was compared to a cohort of 156 children with GBS. The specificity of the Brighton criteria, used for GBS diagnosis, was evaluated in the AFM cohort and the specificity of the Centers for Disease Control and Prevention (CDC) AFM diagnostic criteria in the GBS cohort.
Results
Children with AFM compared to those with GBS had a shorter interval between onset of weakness and nadir (3 vs. 8 days, p < 0.001), more often had asymmetric limb weakness (58% vs. 0%, p < 0.001), and less frequently had sensory deficits (0% vs. 40%, p < 0.001). In AFM, cerebrospinal fluid leukocyte counts were higher, whereas protein concentrations were lower. Spinal cord lesions on magnetic resonance imaging were only found in AFM patients. No GBS case fulfilled CDC criteria for definite AFM. Of the AFM cases, 8% fulfilled the Brighton criteria for GBS, when omitting the criterion of excluding an alternate diagnosis.
Conclusions
Despite the overlap in clinical presentation, we found distinctive early clinical and diagnostic characteristics for differentiating AFM from GBS in children. Diagnostic criteria for AFM and GBS usually perform well, but some AFM cases may fulfill clinical diagnostic criteria for GBS. This underlines the need to perform diagnostic tests early to exclude AFM in children suspected of atypical GBS